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Abstract
Background: Increased stillbirth rates occur among HIV-infected women, but no studies have evaluated the pathological
basis for this increase, or whether highly active antiretroviral therapy (HAART) influences the etiology of stillbirths. It is also
unknown whether HIV infection of the fetus is associated with stillbirth.
Methods: HIV-infected women and a comparator group of HIV-uninfected women who delivered stillbirths were enrolled at
the largest referral hospital in Botswana between January and November 2010. Obstetrical records, including antiretroviral
use in pregnancy, were extracted at enrollment. Verbal autopsies; maternal HIV, CD4 and HIV RNA testing; stillbirth HIV PCR
testing; and placental pathology (blinded to HIV and treatment status) were performed.
Results: Ninety-nine stillbirths were evaluated, including 62 from HIV-infected women (34% on HAART from conception, 8%
on HAART started in pregnancy, 23% on zidovudine started in pregnancy, and 35% on no antiretrovirals) and 37 from a
comparator group of HIV-uninfected women. Only 2 (3.7%) of 53 tested stillbirths from HIV-infected women were HIV PCR
positive, and both were born to women not receiving HAART. Placental insufficiency associated with hypertension
accounted for most stillbirths. Placental findings consistent with chronic hypertension were common among HIV-infected
women who received HAART and among HIV-uninfected women (65% vs. 54%, p=0.37), but less common among HIV-
infected women not receiving HAART (28%, p=0.003 vs. women on HAART).
Conclusions: In utero HIV infection was rarely associated with stillbirths, and did not occur among women receiving HAART.
Hypertension and placental insufficiency were associated with most stillbirths in this tertiary care setting.
Citation: Shapiro RL, Souda S, Parekh N, Binda K, Kayembe M, et al. (2012) High Prevalence of Hypertension and Placental Insufficiency, but No In Utero HIV
Transmission, among Women on HAART with Stillbirths in Botswana. PLoS ONE 7(2): e31580. doi:10.1371/journal.pone.0031580
Editor: Sten H. Vermund, Vanderbilt University, United States of America
Received December 16, 2011; Accepted January 9, 2012; Published February 22, 2012
Copyright:  2012 Shapiro et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a grant from the Centers for Disease Control and Prevention (U2GPS000941), and by a Research Fellowship from the Doris
Duke Charitable Research Foundation (N.P.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: rshapiro@hsph.harvard.edu
Introduction
Increased stillbirth rates occur among HIV-infected women, but
no studies have evaluated the pathological basis for this increase,
or whether highly active antiretroviral therapy (HAART)
influences the etiology of stillbirths. It is also unknown whether
HIV infection of the fetus is associated with stillbirth.
Several studies from the pre-HAART era demonstrate an
increase in stillbirth among HIV-infected women [1–3], including
a 1998 meta-analysis that demonstrated an odds ratio of 3.91 (95%
CI 2.65–5.77) for stillbirth among HIV-infected women [4]. In
some studies, women with lower CD4 cell count have had a higher
stillbirth risk [1,3,5]. In the HAART era, national surveillance in
the United Kingdom found that women receiving HAART may
have had a higher risk for stillbirth than those taking one or two
antiretrovirals (AOR 2.27, 95% CI, 0.96–5.41) [6]. However,
other studies have not demonstrated excess stillbirth risk with
HAART [7–9]. Only one previous study, from the pre-HAART
era, has evaluated the HIV status of stillbirths to determine
whether acute fetal HIV infection is associated with stillbirth
events [3].
These previous studies suggest a complex relationship between
HIV, HAART, and stillbirth that requires further evaluation of
causal mechanisms. Few studies have performed pathologic
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31580placental examinations among HIV-infected women [10–15], and
none to our knowledge have focused specifically on stillbirth, or
the relationship between HAART and stillbirth. Therefore, we
sought to identify the causes of stillbirth among a selected cohort of
HIV infected and HIV uninfected women through HIV DNA
PCR testing of stillbirths, pathologic examination of placentas, and
detailed verbal autopsies.
Methods
Between January 26 and November 26, 2010, we identified
women who had delivered stillbirths at Princess Marina Hospital
(PMH) in Gaborone, Botswana. PMH is the largest hospital in
Botswana, and serves as a general delivery site as well as a referral
center for high-risk deliveries in southern Botswana (which is a
non-malarial region). The Health Research Development Com-
mittee from Botswana and the Harvard School of Public Health
Office of Human Research Administration approved the study
protocol. Written informed consent was obtained from all
participants.
We asked women who experienced stillbirth at .19 weeks
gestation (as determined by available obstetric records) to enroll in
the study if they were willing to provide informed consent, had a
placenta saved for potential examination, and agreed to additional
laboratory testing. The target sample size was 100 women, and to
enrich the cohort for HIV-infected women, we limited the
enrollment of HIV-uninfected women to a maximum of 40
women. All HIV-infected women who delivered stillbirths were
sought for potential enrollment, whether receiving HAART,
ZDV, or no antiretrovirals. All antiretrovirals were provided by
the Botswana government to its citizens according to national
guidelines (non-citizens were required to purchase the recom-
mended antiretrovirals). HAART was offered for maternal
treatment, either before or during pregnancy, for CD4 cell counts
,250 cells/mm
3 or an AIDS-defining illness. ZDV was offered to
those who did not qualify for treatment, starting at 28 weeks of
pregnancy. Nadir CD4 cell counts were available for only a small
number of women from the medical records and could not be
analyzed. Pre-HAART HIV RNA testing is not routinely
performed in the Botswana treatment program.
Abstracted obstetrical records were used to obtain details of the
pregnancy, maternal medical history, antiretroviral receipt in
pregnancy (for HIV-infected women), and information about the
delivery. A maternal questionnaire and verbal autopsy tool was
used to confirm data from the obstetrical record and to identify
additional information about the pregnancy and delivery. Women
with unknown HIV status, and women who tested HIV negative
.12 weeks before delivery, were offered HIV testing by rapid
ELISA. Among HIV-infected women, HIV RNA testing (COBAS
Amplicor HIV-1 Monitor Test v.1.5, Roche Molecular Systems
Inc., New Jersey, USA) and CD4 cell count testing were
performed, and HIV DNA PCR testing of blood obtained by
cardiac puncture was performed for the stillborn fetus (qualitative
DNA Amplicor HIV-1 test, Roche Diagnostic Systems, New
Jersey, USA). All stillbirths were weighed and examined by a study
physician for congenital abnormalities.
Placental Pathology
The placentas were examined fresh using a standard template
for gross descriptions and sampling. The placentas were grossly
examined, weighed, and trimmed of cord and membranes. The
placentas were sampled making duplicate blocks of proximal and
distal umbilical cord, full thickness parenchyma, and any lesions
grossly appreciated. The samples were fixed in formalin and
processed at the Botswana National Health Laboratory using
standard protocols into paraffin blocks. The blocks were divided
and one set was transported to the Massachusetts General Hospital
in Boston for routine 5 mm sectioning and H&E staining.
The placental pathology was interpreted by one pathologist
(DJR) who had available the gross examination findings,
gestational age as determined at delivery, fetal weight and gross
findings (e.g. maceration, edema, gross malformations, etc.). The
pathologist was blinded to all other clinical data including
maternal and fetal HIV status, treatment, maternal blood pressure
and evidence of infection. The histology was evaluated per usual
standards for an experienced placental/perinatal pathologist and a
diagnostic findings score sheet was completed for each case.
Placental pathology diagnostic criteria were as follows: Acute
placental insufficiency was defined as evidence of acute abruption, or
two of the following: indenting, adherent, retroplacental hemato-
ma intravillous hemorrhage, absence of chronic hypertensive
findings, or marked increase in immature red cells circulating in
fetal vessels. Chronic placental insufficiency was defined as two of the
following: fetal/placental weight ratio .8, chronic abruption
(retroplacental hematoma indenting and infarcting the parenchy-
ma), placental infarcts, decidual vasculopathy, increased and
enlarged syncytial trophoblastic knots (.1 knot per 3 villi or .10
nuclei per knot or knots larger in size than villi), or cord diameter
,1 cm. Infection was defined as any of the following findings: acute
chorioamnionitis with fetal vascular involvement, chorionic
abscesses, diffuse chronic or acute villitis. Stillbirths were
categorized as unknown if there were no significant placental
pathologic findings that met the above definitions.
The target sample size was chosen to balance the feasibility and
cost of performing specialized pathologic testing of placentas and
fetal HIV PCR testing, while allowing for 80% power (with an
alpha level of 0.05) to detect true differences of at least 30% for
most comparisons. Differences of smaller magnitude were
considered less likely to have public health significance. Data
were analyzed in SAS (v.9.1). Associations with pathologic
diagnoses were performed using chi square testing or by univariate
logistic regression. Characteristics were compared between groups
by chi square testing, or by rank-based Spearman or Wilcoxon
testing.
Results
In total, 6,192 women delivered at PMH during the study
period, and 29% were HIV-infected. There were 251 stillbirths;
105 (42%) were among HIV-infected women, 119 (47%) among
HIV-uninfected women, and 27 (11%) among women with
unknown HIV status. We enrolled 99 women with a confirmed
HIV status (accounting for 40% of all women experiencing
stillbirth during the study period). Demographic data for HIV-
infected and HIV-uninfected women included in the study did not
differ substantially from surveillance data collected among all
women who delivered stillbirths in the study period (data not
shown). Our cohort was enriched for HIV infection, and included
62 (62%) who were HIV-infected, and 37 (37%) who were HIV-
uninfected. Maternal characteristics by HIV status are shown in
Table 1. Among HIV-infected women, maternal demographics
were similar for those on or off HAART, except only 1 non-citizen
received HAART in pregnancy (p=0.04).
Among the 62 HIV-infected women, 26 (42%) were receiving
HAART at the time of the stillbirth (81% from prior to
conception, and 19% started during pregnancy); 14 (23%) were
receiving zidovudine (ZDV) alone from a median gestation of 28
weeks, and 22 (35%) had not received antiretrovirals. A nevirapine
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received HAART. The median CD4 cell count at the time of the
stillbirth delivery was 377 (range 104, 1953) cells/mm
3 for those
receiving HAART and 353 (range 44, 937) cells/mm
3 for those
not receiving HAART (p=0.93). At delivery, median HIV RNA
was ,400 (range ,400 to 22,339) copies/mL for women on
HAART, and 8,630 (range ,400, 714,000) copies/mL for women
not receiving HAART (p,0.001).
Delivery characteristics and stillbirth characteristics are shown
in Table 2. The median gestational age at the time of stillbirth
delivery was 31 weeks for both HIV-infected and HIV-uninfected
women. For HIV-infected women, delivery characteristics were
similar by HAART status. Median gestational age at delivery was
30 weeks for those on HAART and 32 weeks for those not on
HAART (p=0.23). Among the 62 HIV-infected women, 53
stillbirths (85%) had successful cardiac puncture for HIV PCR
testing, and only 2 (3.7%) were HIV-infected. The first of these
stillbirths occurred at 32 weeks’ gestation, in a woman with HIV
RNA of 31,400 copies/mL and CD4 cell count of 511 cells/mm
3,
receiving ZDV for the previous 5 weeks. The second occurred at
Table 1. Characteristics of Women Delivering Stillbirths, by HIV Status, Botswana.
Maternal Characteristic HIV-infected women HIV-uninfected women (N=37)
Receiving HAART (N=26) Not Receiving HAART (N=36)
Age (median) 32 yrs
" 30 yrs
" 27 yrs
"
Botswana citizen 25 (96%)
1 28 (78%)
1 33 (89%)
Education
Primary 5 (19%) 7 (19%) 4 (11%)
Secondary 18 (69%) 26 (72%) 25 (68%)
Tertiary 3 (12%) 2 (6%) 6 (16%)
None/unknown 0 (0%) 1 (3%) 2 (5%)
Salaried employment 17 (65)% 14 (38%) 22 (59%)
Referred to PMH for complicated pregnancy or
delivery
22 (85%) 34 (94%) 29 (78%)
Primigravidus 2 (8%) 7 (19%) 12 (32%)
Nulliparous 4 (15%)
" 8 (22%)
" 14 (38%)
"
Past stillbirth 5 (19%) 2 (6%) 5 (14%)
Hypertension in pregnancy* 14 (54%) 17 (47%) 19 (51%)
Preeclampsia/eclampsia in pregnancy** 6 (23%) 7 (19%) 8 (22%)
Antibiotics in pregnancy 14 (54%) 15 (42%) 13 (35%)
Median hemoglobin in pregnancy 11.3 g/dL 11.6 g/dL 11.1 g/dL
*Measured systolic blood pressure $140 mm Hg or diastolic blood pressure $90 mm Hg, or diagnosed with hypertension in pregnancy prior to the onset of labor.
**Presence of hypertension, proteinuria, edema, +/2 seizure.
1P-value ,0.05 for difference between women receiving HAART vs. not receiving HAART.
"P-value ,0.05 for difference between HIV-uninfected women vs. all HIV-infected women.
doi:10.1371/journal.pone.0031580.t001
Table 2. Characteristics of Deliveries, Stillbirths, and Placentas, by HIV Status, Botswana.
Delivery/Stillbirth Characteristic HIV-infected women HIV-uninfected women (N=37)
Receiving HAART (N=26) Not Receiving HAART (N=36)
Median gestation at delivery (range) 30 (24, 42) weeks 32 (24, 42) weeks 31 (22, 37) weeks
% delivered at term (./=37 weeks) 3 (12%) 8 (22%) 2 (5%)
Vaginal Delivery 25 (96%) 35 (97%) 36 (97)%
Fetal heart heard on admission 7 (27%) 4 (11%) 9 (24%)
Median trimmed weight of placenta (range) 170 (80, 515) g
1 248 (75, 845) g
1 230 (100, 930) g
Median weight of stillbirth (range) 885 (460, 2640) g
1 1345 (710, 3540) g
1 1170 (540, 3600) g
Macerated stillbirth 18 (69%) 26 (72%) 23 (62%)
Male gender 15 (58%) 19 (53%) 18 (49%)
Congenital abnormalities present 1 (4%)
" 0 (0%)
" 5 (14%)
"
HIV-infected stillbirth by DNA PCR 0 (0%) 2 (3.7%) –
1P-value ,0.05 for difference between women receiving HAART vs. not receiving HAART.
"P-value ,0.05 for difference between HIV-uninfected women vs. all HIV-infected women.
doi:10.1371/journal.pone.0031580.t002
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copies/mL and CD4 cell count of 44 cells/mm
3, receiving no
antiretrovirals in pregnancy. Both had placental pathology
indicative of infection (necrotizing funisitis). Neither woman had
a reason identified for the stillbirth at the time of the event.
Placental pathology results are shown in Table 3, by maternal
HIV status and antiretroviral exposure status. Placental insuffi-
ciency, with features strongly suggestive of chronic placental
hypertensive damage, accounted for more than half of all stillbirths
in both HIV infected and HIV-uninfected women. Among women
with these pathologic findings, 11 were acute, 43 were chronic,
and 4 were both acute and chronic. Figure 1a demonstrates a
placenta with the typical features of acute and chronic hyperten-
sion. Of women with evidence of placental insufficiency, 71% had
evidence of peripheral hypertension prior to delivery, as indicated
by a blood pressure measurement $140 mm Hg systolic or
$90 mm Hg diastolic, or by a recorded diagnosis of hypertension
during pregnancy. Of these, 73% were noted to have started an
antihypertensive agent prior to delivery. Only 2 women with
placental insufficiency had no recorded blood pressure or
hypertension diagnosis in pregnancy. Preeclampsia (with docu-
mented proteinuria and edema) was reported in 18% of women,
and eclampsia in 3%, and these did not differ by HIV status.
Compared with all other women, those with placental insufficiency
were more likely to report headache in pregnancy (45% vs. 17%,
p=0.003), to report puffy face in pregnancy (30% vs. 8%,
p=0.008), to require an induction of labor for intrauterine fetal
demise (57% vs. 21%, p=0.0005), and to report smaller than
normal size of the stillborn (80% vs. 60%, p=0.03).
Among HIV-infected women, placental insufficiency was more
common among women who had received HAART than among
those who had not received HAART (65% vs. 28%, p=0.003)
(Figure 2). Placental findings suggestive of acute hypertensive
changes were not associated with HAART use; only 1 HIV-
infected women with such findings received HAART. All but one
women receiving HAART had a suppressed HIV RNA ,400
copies/mL at delivery, so this variable could not be analyzed
separately from HAART use itself. Similarly, only 5 women
started HAART during pregnancy, so comparisons between
HAART from conception vs. starting in pregnancy were limited.
CD4 cell count was not associated with either acute or chronic
placental insufficiency; however, median CD4 cell count at
delivery was .350 cells/mm
3 in both HAART-treated and
untreated women.
Among HIV-uninfected women, the percentage with placental
insufficiency with features suggestive of chronic hypertensive
damage was similar to the HAART-treated HIV-infected women
(54% vs. 65%, p=0.37), and there were few women with acute
placental insufficiency (8%). As with the HAART treated women,
placental insufficiency was significantly more common than
among HIV-infected women who were not receiving HAART
(54% vs. 28%, p=0.02) (Figure 2). Female stillbirth gender was
noted in 70% of HIV-uninfected women with placental insuffi-
ciency (p=0.005), although gender was equally balanced in HIV-
infected women with placental insufficiency (49% female,
p=0.54).
Pathologic evidence of infection was identified in 21% of
placentas from HIV-infected women, and in 22% of placentas
from HIV-uninfected women (p=0.94). Among HIV-infected
women, CD4 cell count, HIV RNA, or HAART use were not
associated with placental infection. Fewer maternal delivery
complications were reported among women with infection
compared with other women (9% vs. 53%, p=0.0003), and more
women with infection had $24 hours between membrane rupture
and delivery (29% vs. 2%, p=0.0001). Figure 1b shows placental
pathology typical for infection and other non-hypertensive causes.
There were no placentas with evidence of cytomegalovirus (CMV)
infection. Necrotizing funisitis was only seen in the two stillbirths
that were HIV-infected by PCR testing.
Pathologic fetal findings and congenital abnormalities were
more common among stillbirths of HIV-uninfected women (14%
vs. 2%, p=0.02), and abnormalities included hydrops fetalis (1);
hydrops fetalis with limb abnormalities (1); hydrops fetalis with
hydrocephalus and multiple abnormalities (1); hydrocephalus (1);
genito-urinary malformation (1); and rectal prolapse (1). Nuchal
cord was described in 13% of deliveries, but placental pathology
suggested an alternate underlying cause of the stillbirth for all but
2 of these deliveries.
Discussion
We performed HIV PCR stillbirth testing and placental
pathology in a large cohort of HIV-infected women delivering
stillbirths at a referral hospital in Botswana. In utero HIV infection
was rarely associated with stillbirths, and did not occur among
those receiving HAART. Chronic placental insufficiency with
features of hypertensive damage to the placenta was associated
with the majority of stillbirths among HAART-treated women,
and was also common among a comparator group of HIV-
uninfected women. However, HIV-infected women not receiving
HAART had lower rates of placental insufficiency.
Only one previous study has evaluated in utero HIV infection
among stillbirths or miscarriages, finding 7 of 14 infections by in
situ hybridization [3]. This pre-HAART era study was performed
on women without any antiretroviral treatment in pregnancy, and
Table 3. Placental Pathology Results, by HIV Status and ARV Exposure, Botswana.
Placental Pathology
HIV+ HAART in pregnancy
(N=26)
HIV+ ZDV in pregnancy
(N=14)
HIV+ No ARVs in pregnancy
(N=22) HIV- (N=37)
Chronic placental insufficiency 17 (65%)
1 6 (43%)
1 4 (18%)
1 20 (54%)
Acute placental insufficiency* 1 (4%) 1 (7%) 6 (27%) 3 (8%)
Infection 4 (15%) 3 (21%) 6 (27%) 8 (22%)
Other
1 2 (8%) 2 (14%) 0 (0%) 3 (8%)
Unknown 2 (8%) 2 (14%) 6 (27%) 3 (8%)
*4 women with both acute and chronic placental insufficiency were categorized as chronic.
1Other=maternal floor infarct (2), hydrops fetalis (2), villous maturational arrest (1), massive chronic intervillositis/villitis of unknown/unclear etiology (1), massive
perivillous fibrin (1).
doi:10.1371/journal.pone.0031580.t003
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maternal immunosuppression. Of importance, 4 of the 7
transmissions in that study occurred at ,20 weeks gestation; our
study did not evaluate fetal losses at these early gestational ages. In
our cohort, we report far lower vertical HIV transmission, even
among untreated or ZDV-only treated women (1/22 and 1/14,
respectively). Transmission did not exceed the expected amount of
in utero MTCT for a cohort of live infants. It is unsurprising that no
transmission occurred among women receiving HAART, as would
be common for a series of this size evaluating live infants. In sum,
our HIV DNA PCR results suggest that transmission to stillbirths
probably follows a similar pattern as for live infants. Placental
evaluation from both transmitting women showed findings
consistent with an infectious cause of the stillbirths, with severe
acute chorioamnionitis with fetal involvement, including the only
cases in the series with necrotizing funisitis. We suspect, but cannot
prove, that acute in utero HIV infection was the source of these
findings and precipitated these two stillbirths.
The frequency of chronic placental insufficiency as the likely
cause of stillbirths among both HIV-infected and HIV-uninfected
women was surprising, as infectious etiologies are more commonly
reported in low and middle income countries [16]. Although most
women with chronic placental insufficiency had received a
diagnosis of hypertension during pregnancy and had started an
antihypertensive agent at some point during pregnancy, hyper-
tension was diagnosed near delivery in many cases. However, we
do not have complete information about treatment duration, and a
more detailed review of hypertension management in Botswana is
warranted. More than a quarter of women with chronic placental
insufficiency had no suggestion of hypertension in pregnancy by
recorded blood pressure readings or obstetrical diagnoses. While
this may represent subclinical hypertension (which would add
substantially to the challenge of diagnosing and managing this
problem), a more likely explanation is lack of detection and the
need for more aggressive hypertensive monitoring in pregnancy.
Placental findings did not differ among women with or without
hypertension detected during pregnancy.
HAART appeared to restore – or possibly exacerbate – the
underlying risk for placental insufficiency among HIV-infected
women, and those not receiving HAART had a lower risk for this
complication. This finding is consistent with studies of preeclamp-
sia and fetal death among HAART-exposed and HAART–
unexposed women in European studies. In Spain, preeclampsia
and fetal death rates were very low among HIV-infected women in
the pre-HAART era, but jumped above background rates during
the HAART era [17]. In the United Kingdom, preeclampsia was
not reported among a cohort of HIV-infected women who did not
receive HAART, but increased to a rate similar to HIV-uninfected
controls among those receiving HAART [18]. Our findings are
consistent with this literature, and suggest a hypertensive spectrum
associated with HAART use that ranges from overt preeclampsia
to unrecognized hypertension leading to stillbirths. A proposed
mechanism for this ‘‘restoration’’ of risk is a shift in cytokine
environment or heightened fetal antigen recognition with immune
reconstitution [18], although data to support this hypothesis are
lacking. The fact that most women in our study had been receiving
HAART from before conception argues against an acute
reconstitution event as the driving risk factor. However, few
women in our study started HAART in pregnancy, and our study
design could not evaluate stillbirth incidence by duration of
HAART exposure. Finally, it remains unclear whether the risk of
stillbirth from placental insufficiency exceeds the risk in the general
population, or whether HAART merely restores the background
risk. The high overall proportion of HIV-infected women
delivering stillbirths at PMH during the study period (42%) may
argue for the former.
Figure 1. Figure 1a and Figure 1b. Figure 1a. H&E stains of
placentas with typical characteristics of hypertension, Botswana. A.
Distal villous hyperplasia – small round and elongate villi with large
syncytial trophoblastic knots and abundant intervillous space. B. Severe
decidual vasculopathy with atherosis. C.Chronic abruption. Figure 1b.
H&E stains of placentas with infection and other non-hypertensive
findings: A,B, and C are examples of findings that support and infectious
cause of death: A. Necrotizing Funisitis – umbilical vein with transmural
inflammation and necrotic neutrophil debri as a halo in Wharton’s jelly.
B. Acute villitis/microscopic abcess. C. Acute chorioamnionitis with
multiple bacterial cocci present. D and E are other non-infectious
findings: D. Villous maturational arrest (a term placenta with immature
villi and centralized vessels) E. Hydrops placentalis – this placenta
weighed .900 grams and showed diffuse acute villous edema.
doi:10.1371/journal.pone.0031580.g001
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percentage of total stillbirths included during the study period; the
inclusion of an HIV-uninfected comparator group; and the
availability of detailed verbal autopsy and medical record data,
laboratory testing (including DNA PCR testing), and placental
pathology. Limitations included lack of ultrasound dating for
gestational ages, self-report of several factors, and limited blood
pressure measurements and antihypertensive treatment histories
during pregnancy. We could not distinguish potential effects of
different HAART regimens, because most received NVP-based
HAART. Maternal treatment regimens were linked to disease
status, and although CD4 cell counts were similar for HAART-
treated and non-treated women, we cannot exclude underlying
disease severity as a potential confounder of stillbirth etiology
(HAART-treated women were likely to have had a CD4 ,250
cells/mm
3 or AIDS-defining illness at HAART initiation, but this
could not be documented from available records).
We believe that stillbirths at PMH not included in this study
were the result of logistics (rapid discharge or burial) and the
intentional limitation of HIV-uninfected women, and did not
represent unrecognized systematic bias. We did not detect
differences in key indicators between women in our cohort and
all women who delivered stillbirths at PMH in the same time
period. PMH is the largest general maternity ward in the country,
and it is also a referral center for high-risk deliveries that may end
in stillbirths, as was reported for the majority of this cohort.
Although referral bias is a possibility, we estimate that PMH
delivers up to half of all stillbirths that occur in hospitals in
southern Botswana (BHP, unpublished data, 2011), and we believe
this cohort is representative of stillbirths in the region. However,
stillbirth etiologies may differ in other settings. Finally, although
we strongly suspect that pathologic findings associated with the
stillbirths in this study were causative (a belief strengthened by our
rigorous criteria for characterizing placental findings, and the
severe pathology associated with most events), we recognize that
even with ‘‘gold standard’’ pathologic testing we cannot prove
causation. Although placental features similar to chronic hyper-
tensive damage may be detected among women with thrombo-
philia [19], our definitions required a constellation of placental
findings only likely from chronic hypertensive damage.
In summary, we found in utero HIV infection was rarely
associated with stillbirths, but detected a high prevalence of
hypertension and chronic placental insufficiency among HAART-
exposed women and HIV-uninfected women. Although HAART
may reduce stillbirth risk potentially related to in utero HIV
transmission or poor maternal health in pre-HAART era studies,
it appears to restore or possibly increase risk related to placental
insufficiency. However, it is unknown whether antihypertensive
treatment in this setting modifies stillbirth risk, and it is likely that
the severity of hypertension is an important factor in fetal
outcomes [20–23]. A better understating of the relationship
between HAART use and hypertension in pregnancy, and the
mechanism by which HAART may affect chronic placental
hypertensive damage, is needed. In the meantime, because
hypertension in pregnancy is treatable and of potential benefit to
maternal and fetal well-being, efforts to optimize screening and
management of this condition for women receiving HAART are
warranted in Botswana and elsewhere.
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